



PRESS RELEASE

WeHealth by Servier launches Cardioskin™, an ambulatory digital medical device that records cardiac activity in real time

Paris, France – 16 January 2019 – [WeHealth by Servier](#), [Servier](#) Group's e-health Division, has announced the launch in France of Cardioskin™, an ambulatory digital device that continuously records cardiac activity through 15-lead electrocardiogram (ECG) monitoring. This announcement was made during the annual European Days of the French Cardiology Society, held in Paris from 16 to 19 January 2019.

Cardioskin™ is a smart t-shirt that performs 15-lead electrocardiogram monitoring and is available on prescription, under medical supervision. It is made of a light, smart fabric (which can be washed several times) featuring embedded sensors which measure the heart's electrocardiographic activity (ECG) and detect abnormalities, in situations where long-term assessment (more than 24 hours) of the heart's rhythm is required.

The collected data are analyzed and sent to the doctor via the secure Cardioskin™ platform, which is designed to enable rapid, accurate diagnosis and to rapidly determine the best response.

Using a smartphone application and an alert button integrated into the t-shirt, the patient can signal the occurrence of events, thus allowing the doctor to correlate these events with the data collected.

"In cardiovascular medicine, a single requirement dictates the focus of research: quick action. Cardioskin™ meets this requirement by allowing patients to quickly receive personalized care and advice, while improving the daily activities of health care professionals," said Dr. David Guez, Director of WeHealth by Servier. *"The aim of WeHealth by Servier is to develop innovative health care solutions that contribute to improving the global care delivered to patients."*

"It is fantastic to see a new solution to the problem of diagnosing intermittent heart arrhythmia issues that may explain serious conditions such as syncope or stroke. Cardioskin™ has the potential to become an important tool for cardiologists," said Professor Fausto Pinto, Santa Maria University Hospital, Lisbon, Portugal, and former chairman of the European Society of Cardiology.

France is the first country to launch Cardioskin™, which has CE marking and has obtained 510(k) Clearance from the FDA¹. This is the first solution from the WeHealth by Servier portfolio. Ten other solutions are currently under development in fields including oncology, cardiovascular medicine, diabetology, and neurology.

Description of Cardioskin™:

- A smart t-shirt made of a smart fabric featuring 13 integrated electrodes, two batteries, a recorder, and an alert button.
- An application for smartphones and tablets designed for use by patients and doctors.
- A cloud platform available on the Internet with integrated Mortara® analytical software.
- A secure environment for gathered and stored data, accessible by the doctor.

¹ FDA: Food and Drug Administration, a federal agency of the United States Department of Health and Human Services.



About electrocardiograms and cardiovascular diseases:

Today, five types of tool are available to cardiologists and health care professionals:

- ECG, performed from the patient's bedside or in the doctor's office: recording time is very short.
- Traditional Holter monitoring: based on several patches attached to the skin and connected to a box, this is used to analyze retroactively any abnormalities recorded over a monitoring period of one day to three weeks maximum.
- Adhesive patches allow 1-lead recording, which does not always enable a reliable diagnosis.
- Other digital tools (such as watches) require operation by the patient and only perform intermittent monitoring.
- Implants, which require a prior surgical procedure.

In many cases, low performance levels have been observed, making it necessary to redo the exams. So, there is an urgent need for a device that offers long-term monitoring. Currently, cardiovascular disease (CVD) is the leading cause of death globally. An estimated 17.9 million² people died from CVD in 2015, representing 31% of all global deaths. Of these deaths, an estimated 7.4 million were due to coronary heart disease and 6.7 million were due to stroke.

About Cardioskin™

Cardioskin™ is a breakthrough ambulatory 15-lead ECG device for long-term patient monitoring. It was developed in collaboration with Bioserenity, a French start-up. Cardioskin™ is a CE marked and 510k FDA US Clearance noninvasive medical device.

About Servier

Servier is an international pharmaceutical company governed by a nonprofit foundation, with its headquarters in France (Suresnes). With a strong international presence in 149 countries and a turnover of 4.152 billion euros in 2017, Servier employs 21 700 people worldwide. Entirely independent, the Group reinvests 25% of its turnover (excluding generic drugs) in research and development and uses all its profits for development. Corporate growth is driven by Servier's constant search for innovation in five areas of excellence: cardiovascular, immune-inflammatory and neuropsychiatric diseases, cancer and diabetes, as well as by its activities in high-quality generic drugs. For further information: www.servier.com

About WeHealth by Servier

Launched in November 2016, WeHealth by Servier, the e-Health division of the Servier Group, aims to improve the daily lives of patients and health professionals alike using digital. WeHealth by Servier proposes innovative digital and connected solutions as well as services by making the most of collected data, to ensure better individual monitoring of the patient and better prediction and prevention of disease progression. In an open innovative approach, WeHealth by Servier identifies the most promising start-ups in e-health, in France and internationally, to co-develop solutions. In this way, WeHealth by Servier contributes to the creation of an ecosystem of partners to facilitate and accelerate the development, industrialization, and distribution of innovations and to render them accessible to the greatest number. For further information: www.wehealthbyservier.com

Follow WeHealth by Servier on social media:  

Press contacts:

Sonia MARQUES: media@servier.com – Tel. +33 (0)1 55 72 40 21 / + 33 (0) 7 84 28 76 13

Karine BOUSSEAU: media@servier.com – Tel. +33 (0)1 55 72 60 37

² Source : Benjamin EJ et al. *Circulation*. 2018;137(12):e67-e492.